ImmunoGen proposes $200M stock offering
ImmunoGen (NASDAQ:IMGN) said Wednesday it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering.
ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of common stock.
All of the shares of common stock to be sold in the offering are to be offered by ImmunoGen.
Net proceeds from the offering will be used to fund operations, including, but not limited to, global commercialization activities, supply of ELAHERE drug product, among other things.
Jefferies, Goldman Sachs, and Guggenheim Securities are acting as joint book-running managers for the proposed offering.